CDK4/6 Market: Is A Shakeup Underway?
Pfizer's Ibrance still dominates the category but sales slowed in the first quarter, while Novartis’s Kisqali and Lilly's Verzenio both grew double digits.
Pfizer's Ibrance still dominates the category but sales slowed in the first quarter, while Novartis’s Kisqali and Lilly's Verzenio both grew double digits.